JP2005524730A5 - - Google Patents

Download PDF

Info

Publication number
JP2005524730A5
JP2005524730A5 JP2004501483A JP2004501483A JP2005524730A5 JP 2005524730 A5 JP2005524730 A5 JP 2005524730A5 JP 2004501483 A JP2004501483 A JP 2004501483A JP 2004501483 A JP2004501483 A JP 2004501483A JP 2005524730 A5 JP2005524730 A5 JP 2005524730A5
Authority
JP
Japan
Prior art keywords
diblock copolymer
valerolactone
polymer
dosage form
polymer block
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004501483A
Other languages
Japanese (ja)
Other versions
JP2005524730A (en
JP4300184B2 (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/004368 external-priority patent/WO2003093344A1/en
Publication of JP2005524730A publication Critical patent/JP2005524730A/en
Publication of JP2005524730A5 publication Critical patent/JP2005524730A5/ja
Application granted granted Critical
Publication of JP4300184B2 publication Critical patent/JP4300184B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Claims (27)

式Ａ−Ｂ
［式中、
ポリマーブロックＡは、＜１，０００の分子量を有する線状の製薬学的に許容され得る親水性ポリマーを示し、
ポリマーブロックＢは、グリコール酸、プロピオラクトン、γ−ブチロラクトン、δ−バレロラクトン、γ−バレロラクトン、ε−カプロラクトン、トリメチレンカーボネート、ｐ−ジオキサノン、テトラメチレンカーボネート、ε−ラクトン、１，５−ジオキセパン−２−オンから選ばれる少なくとも２種のモノマーを含んでなるポリマーを示す］
のジブロックコポリマーであって、ジブロックコポリマーが５０℃より低い温度で液体であることを特徴とするジブロックコポリマー。 Formula AB
[Where:
Polymer block A represents a linear pharmaceutically acceptable hydrophilic polymer having a molecular weight of <1,000,
Polymer block B is glycolic acid, propiolactone, γ-butyrolactone, δ-valerolactone, γ-valerolactone, ε-caprolactone, trimethylene carbonate, p-dioxanone, tetramethylene carbonate, ε-lactone, 1,5- Indicates a polymer comprising at least two monomers selected from dioxepane-2-one]
A diblock copolymer according to claim 1, wherein the diblock copolymer is a liquid at a temperature lower than 50 ° C. ポリマーブロックＢがグリコール酸、プロピオラクトン、γ−ブチロラクトン、δ−バレロラクトン、ε−カプロラクトン、トリメチレンカーボネート、ｐ−ジオキサノン、テトラメチレンカーボネート、ε−ラクトン、１，５−ジオキセパン−２−オン又はそれらの混合物から選ばれるモノマーを含んでなるポリマーを示す請求項１に記載のジブロックコポリマー。   Polymer block B is glycolic acid, propiolactone, γ-butyrolactone, δ-valerolactone, ε-caprolactone, trimethylene carbonate, p-dioxanone, tetramethylene carbonate, ε-lactone, 1,5-dioxepan-2-one or The diblock copolymer according to claim 1, which shows a polymer comprising a monomer selected from a mixture thereof. ポリマーブロックＢがトリメチレンカーボネートのモノマー及びグリコール酸、プロピオラクトン、γ−ブチロラクトン、δ−バレロラクトン、γ−バレロラクトン、ε−カプロラクトン、ｐ−ジオキサノン、テトラメチレンカーボネート、ε−ラクトン、１，５−ジオキセパン−２−オン又はそれらの混合物から選ばれるモノマーを含んでなるポリマーを示す請求項１に記載のジブロックコポリマー。 Polymer block B is trimethylene carbonate monomer and glycolic acid, propiolactone, γ-butyrolactone, δ-valerolactone, γ-valerolactone, ε-caprolactone, p-dioxanone, tetramethylene carbonate, ε-lactone, 1,5 The diblock copolymer according to claim 1 , which indicates a polymer comprising a monomer selected from dioxepane-2-one or mixtures thereof. ポリマーブロックＢがトリメチレンカーボネートのモノマー及びグリコール酸、プロピオラクトン、γ−ブチロラクトン、δ−バレロラクトン、ε−カプロラクトン、ｐ−ジオキサノン、テトラメチレンカーボネート、ε−ラクトン、１，５−ジオキセパン−２−オン又はそれらの混合物から選ばれるモノマーを含んでなるポリマーを示す請求項３に記載のジブロックコポリマー。   Polymer block B is trimethylene carbonate monomer and glycolic acid, propiolactone, γ-butyrolactone, δ-valerolactone, ε-caprolactone, p-dioxanone, tetramethylene carbonate, ε-lactone, 1,5-dioxepane-2- 4. A diblock copolymer according to claim 3, which shows a polymer comprising monomers selected from on or mixtures thereof. ポリマーブロックＢがプロピオラクトン、γ−ブチロラクトン、δ−バレロラクトン、γ−バレロラクトン、ε−カプロラクトン、トリメチレンカーボネート、ｐ−ジオキサノン、テトラメチレンカーボネート、ε−ラクトン、１，５−ジオキセパン−２−オンから選ばれるモノマーを含んでなるポリマーを示す請求項１に記載のジブロックコポリマー。   Polymer block B is propiolactone, γ-butyrolactone, δ-valerolactone, γ-valerolactone, ε-caprolactone, trimethylene carbonate, p-dioxanone, tetramethylene carbonate, ε-lactone, 1,5-dioxepane-2- The diblock copolymer according to claim 1, which shows a polymer comprising a monomer selected from ON. ポリマーブロックＢがプロピオラクトン、γ−ブチロラクトン、δ−バレロラクトン、γ−バレロラクトン、ε−カプロラクトン、トリメチレンカーボネート、ｐ−ジオキサノン、テトラメチレンカーボネート、ε−ラクトン、１，５−ジオキセパン−２−オンから選ばれる２種のモノマーを含んでなる請求項５に記載のジブロックコポリマー。 Polymer block B is propiolactone, γ-butyrolactone, δ-valerolactone, γ-valerolactone, ε-caprolactone, trimethylene carbonate, p-dioxanone, tetramethylene carbonate, ε-lactone, 1,5-dioxepane-2- The diblock copolymer according to claim 5 , comprising two monomers selected from ON. ポリマーブロックＢがε−カプロラクトン及びトリメチレンカーボネートから選ばれるモノマーを含んでなる請求項６に記載のジブロックコポリマー。 The diblock copolymer according to claim 6 , wherein the polymer block B comprises a monomer selected from ε-caprolactone and trimethylene carbonate. 式Ａ−ＢFormula AB
［式中、[Where:
ポリマーブロックＡは、＜１，０００の分子量を有する線状の製薬学的に許容され得る親水性ポリマーを示し、Polymer block A represents a linear pharmaceutically acceptable hydrophilic polymer having a molecular weight of <1,000,
ポリマーブロックＢは、トリメチレンカーボネートのモノマー及びグリコール酸、プロピオラクトン、γ−ブチロラクトン、δ−バレロラクトン、ε−カプロラクトン、トリメチレンカーボネート、ｐ−ジオキサノン、テトラメチレンカーボネート、ε−ラクトン、１，５−ジオキセパン−２−オン又はそれらの混合物から選ばれるモノマーを含んでなるポリマーを示す］Polymer block B comprises trimethylene carbonate monomer and glycolic acid, propiolactone, γ-butyrolactone, δ-valerolactone, ε-caprolactone, trimethylene carbonate, p-dioxanone, tetramethylene carbonate, ε-lactone, 1,5 -Represents a polymer comprising a monomer selected from dioxepane-2-one or mixtures thereof]
のジブロックコポリマーであって、ジブロックコポリマーが５０℃より低い温度で液体であることを特徴とするジブロックコポリマー。A diblock copolymer according to claim 1, wherein the diblock copolymer is a liquid at a temperature lower than 50 ° C. ポリマーブロックＡがポリ（Ｃ1-20アルキレンオキシド）又はその誘導体を示す請求項１〜８のいずれか１つに記載のジブロックコポリマー。 The diblock copolymer according to any one of claims 1 to 8 , wherein the polymer block A represents poly (C 1-20 alkylene oxide) or a derivative thereof. ポリ（Ｃ1-20アルキレンオキシド）又はその誘導体がポリ（エチレングリコール）又はその誘導体、特にポリ（エチレングリコール）モノメチルエーテルである請求項９に記載のジブロックコポリマー。 The diblock copolymer according to claim 9 , wherein the poly (C 1-20 alkylene oxide) or a derivative thereof is poly (ethylene glycol) or a derivative thereof, in particular poly (ethylene glycol) monomethyl ether. ポリ（エチレングリコール）又はその誘導体が＞３５０から≦７５０の範囲の分子量を有する請求項１０に記載のジブロックコポリマー。 11. The diblock copolymer according to claim 10 , wherein the poly (ethylene glycol) or derivative thereof has a molecular weight in the range of> 350 to ≦ 750. ポリ（エチレングリコール）又はその誘導体が７５０の分子量を有する請求項１１に記載のジブロックコポリマー。 The diblock copolymer of claim 11 , wherein the poly (ethylene glycol) or derivative thereof has a molecular weight of 750. ２，０００〜１０，０００の範囲の分子量を有する請求項１〜１２のいずれか１つに記載のジブロックコポリマー。 The diblock copolymer according to any one of claims 1 to 12 , having a molecular weight in the range of 2,000 to 10,000. ２，０００〜８，０００の範囲の分子量を有する請求項１３に記載のジブロックコポリマー。 The diblock copolymer of claim 13 having a molecular weight in the range of 2,000 to 8,000. ２，５００〜７，０００の範囲の分子量を有する請求項１４に記載のジブロックコポリマー。 The diblock copolymer of claim 14 having a molecular weight in the range of 2,500 to 7,000. 室温又は３７℃において液体である請求項１〜１５のいずれか１つに記載のジブロックコポリマー。 The diblock copolymer according to any one of claims 1 to 15 , which is a liquid at room temperature or 37 ° C. 活性成分ならびに請求項１〜１６のいずれか１つに記載の式Ａ−Ｂの１種もしくはそれより多いジブロックコポリマーを含んでなり、組成物が５０℃より低い温度で液体であることを特徴とする組成物。 17. A composition comprising an active ingredient and one or more diblock copolymers of the formula AB according to any one of claims 1 to 16 , wherein the composition is liquid at a temperature below 50C. And a composition. 組成物が非−水性である請求項１７に記載の組成物。 18. A composition according to claim 17 , wherein the composition is non-aqueous. 請求項１７又は１８に記載の組成物の治療的に有効な量を含んでなる製薬学的投薬形態物。 A pharmaceutical dosage form comprising a therapeutically effective amount of the composition of claim 17 or 18 . 投薬形態が経口的投与に適していることを特徴とする請求項１９に記載の製薬学的投薬形態物。 20. A pharmaceutical dosage form according to claim 19 , characterized in that the dosage form is suitable for oral administration. 投薬形態が非経口的投与に適していることを特徴とする請求項１９に記載の製薬学的投薬形態物。 20. A pharmaceutical dosage form according to claim 19 , characterized in that the dosage form is suitable for parenteral administration. 投薬形態が水溶液である請求項１９〜２１のいずれか１つに記載の製薬学的投薬形態物。 The pharmaceutical dosage form according to any one of claims 19 to 21 , wherein the dosage form is an aqueous solution. 活性成分及び請求項１〜１６のいずれか１つに記載の１種もしくはそれより多い式Ａ−Ｂのジブロックコポリマーを含んでなる水溶液の調製法であって、活性成分を１種もしくはそれより多い液体コポリマーと、すなわち５０℃より低い温度で混合し、続いて攪拌しながら水を加えることを特徴とする方法。 17. A process for the preparation of an aqueous solution comprising an active ingredient and one or more diblock copolymers of the formula AB according to any one of claims 1 to 16 , comprising one or more active ingredients A process characterized in that it is mixed with a number of liquid copolymers, i.e. at a temperature below 50 ° C., followed by addition of water with stirring. 活性成分及び請求項１〜１６のいずれか１つに記載の１種もしくはそれより多い式Ａ−Ｂのジブロックコポリマーを含んでなる水溶液の調製法であって、
ａ）１種もしくはそれより多いコポリマーを５０℃より低い温度で水と混合し、
続いて
ｂ）ａ）の下に得られるポリマー水溶液に、攪拌しながら活性成分を加える
ことを特徴とする方法。 A process for the preparation of an aqueous solution comprising an active ingredient and one or more diblock copolymers of the formula AB according to any one of claims 1 to 16 , comprising
a) mixing one or more copolymers with water at a temperature below 50 ° C .;
Subsequently, b) adding the active ingredient to the aqueous polymer solution obtained under a) with stirring. 処置の必要のあるヒト又はヒト以外の動物への経口的投与用の製薬学的投薬形態物の製造のための請求項１７又は１８に記載の組成物の使用。 Use of a composition according to claim 17 or 18 for the manufacture of a pharmaceutical dosage form for oral administration to a human or non-human animal in need of treatment. 処置の必要のあるヒト又はヒト以外の動物への非経口的投与用の製薬学的投薬形態物の製造のための請求項１７又は１８に記載の組成物の使用。 Use of a composition according to claim 17 or 18 for the manufacture of a pharmaceutical dosage form for parenteral administration to a human or non-human animal in need of treatment. 容器、請求項１９〜２２のいずれか１つに記載の製薬学的投薬形態物を含んでなり、且つパッケージに記載事項を伴う市販に適した製薬学的パッケージ。 23. A commercially suitable pharmaceutical package comprising a container, the pharmaceutical dosage form according to any one of claims 19 to 22 , and with the package description.
JP2004501483A 2002-05-03 2003-04-24 Polymeric microemulsion Expired - Fee Related JP4300184B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37790102P 2002-05-03 2002-05-03
PCT/EP2003/004368 WO2003093344A1 (en) 2002-05-03 2003-04-24 Polymeric microemulsions

Publications (3)

Publication Number Publication Date
JP2005524730A JP2005524730A (en) 2005-08-18
JP2005524730A5 true JP2005524730A5 (en) 2006-06-08
JP4300184B2 JP4300184B2 (en) 2009-07-22

Family

ID=29401581

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004501483A Expired - Fee Related JP4300184B2 (en) 2002-05-03 2003-04-24 Polymeric microemulsion

Country Status (22)

Country Link
US (3) US20060034797A1 (en)
EP (1) EP1504047B1 (en)
JP (1) JP4300184B2 (en)
KR (1) KR20040111466A (en)
CN (1) CN1290893C (en)
AR (1) AR039522A1 (en)
AT (1) ATE380834T1 (en)
AU (1) AU2003222310B2 (en)
BR (1) BR0309688A (en)
CA (1) CA2483282C (en)
DE (1) DE60318035T2 (en)
EA (1) EA008244B1 (en)
ES (1) ES2298510T3 (en)
IL (1) IL164977A (en)
MX (1) MXPA04010778A (en)
MY (1) MY139066A (en)
NO (1) NO20045283L (en)
NZ (1) NZ536294A (en)
PL (1) PL220850B1 (en)
TW (1) TWI310388B (en)
WO (1) WO2003093344A1 (en)
ZA (1) ZA200408854B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en) * 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JO3429B1 (en) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv Hiv inhibiting pyrimidines derivatives
WO2004016581A1 (en) * 2002-08-09 2004-02-26 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US20060024337A1 (en) * 2002-10-21 2006-02-02 Jean-Thierry Simonnet Process for dissolving lipophilic compounds in aqueous solution with amphiphilic block copolymers, and cosmetic composition
US7968115B2 (en) * 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
US8784881B2 (en) 2004-03-05 2014-07-22 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
JP4929567B2 (en) * 2004-08-05 2012-05-09 コニカミノルタエムジー株式会社 Method for producing preparation containing polymer micelle
UA91520C2 (en) * 2004-09-29 2010-08-10 Баер Шеринг Фарма Акциенгезельшафт Thermodynamically stable form of tosylate
US7888380B2 (en) * 2004-10-08 2011-02-15 Janssen Pharmaceutica, N.V. 1,2,4-Triazolylaminoaryl (heteroaryl) sulfonamide derivatives
US7202209B2 (en) * 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
WO2007030680A2 (en) 2005-09-07 2007-03-15 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as axl inhibitors
JP4892264B2 (en) * 2006-03-30 2012-03-07 高田製薬株式会社 Risperidone aqueous solution
WO2007136134A1 (en) * 2006-05-23 2007-11-29 Nanocarrier Co., Ltd. Process for producing polymer micelle enclosing hydrophobic drug
KR100795214B1 (en) * 2006-08-22 2008-01-21 이화여자대학교 산학협력단 Thermogelling poly(ethylene glycol)/polycarbonate block copolymer and preparation method thereof
AR062927A1 (en) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4- ([[4- CHLORINE-3- (TRIFLUOROMETILE) PHENYL) CARBAMOIL] AMINO] -3- FLUOROPHENOXY) -N- METHYLPIRIDIN-2-MONOHIDRATED CARBOXAMIDE
JP2010509253A (en) * 2006-11-09 2010-03-25 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 4- [4-({[4-Chloro-3- (trifluoromethyl) phenyl] carbamoyl} amino) -3-fluorophenoxy] -N-methylpyridine-2-carboxamide polymorph III
JP2010509382A (en) * 2006-11-14 2010-03-25 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Polymorph II of 4- [4-({[4-Chloro-3- (trifluoromethyl) phenyl] carbamoyl} amino) -3-fluorophenoxy] -N-methylpyridine-2-carboxamide II
PT2114955E (en) 2006-12-29 2013-04-18 Rigel Pharmaceuticals Inc Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
CA2710043C (en) 2006-12-29 2016-02-09 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
ES2656496T3 (en) 2006-12-29 2018-02-27 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as AXL inhibitors
PL2078010T3 (en) 2006-12-29 2014-07-31 Rigel Pharmaceuticals Inc Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2008083354A1 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors
KR20150064232A (en) 2007-05-25 2015-06-10 더 유니버시티 오브 브리티쉬 콜롬비아 Formulations for the oral administration of therapeutic agents and related methods
FR2919296A1 (en) * 2007-07-25 2009-01-30 Rhodia Operations Sas OPENING EPOXY CYCLES BY CARBENES.
SI2205592T1 (en) 2007-10-26 2013-09-30 Rigel Pharmaceuticals, Inc. Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
JP5592884B2 (en) 2008-07-09 2014-09-17 ライジェル ファーマシューティカルズ， インコーポレイテッド Polycyclic heteroaryl substituted triazoles useful as AXL inhibitors
WO2010005879A1 (en) 2008-07-09 2010-01-14 Rigel Pharmaceuticals, Inc. Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
SG196774A1 (en) 2008-12-24 2014-02-13 Tibotec Pharm Ltd Implantable devices for treating hiv
EP2201935B1 (en) * 2008-12-26 2020-07-08 Samyang Biopharmaceuticals Corporation Polymeric micelle composition containing a poorly soluble drug and preparation method of the same
CN101444510B (en) * 2008-12-31 2011-03-09 南京卡文迪许生物工程技术有限公司 Pharmaceutical preparation containing voriconazole and preparation method thereof
PT2387395E (en) 2009-01-16 2015-02-04 Rigel Pharmaceuticals Inc Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
CN101531756B (en) * 2009-04-16 2011-06-15 山东大学 Method for preparing water soluble polyethylene glycol/polylactic segmented polycarbonate resin
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
KR20120104975A (en) 2009-10-01 2012-09-24 앱탈리스 파마테크, 인코포레이티드 Orally administered corticosteroid compositions
WO2011050457A1 (en) 2009-10-26 2011-05-05 The University Of British Columbia Stabilized formulation for oral administration of therapeutic agents and related methods
SG191414A1 (en) * 2010-12-29 2013-08-30 Medincell Biodegradable drug delivery compositions
EP2634179A1 (en) * 2012-02-28 2013-09-04 Sanofi Functional PLA-PEG copolymers, the nanoparticles thereof, their preparation and use for targeted drug delivery and imaging
ITTO20130431A1 (en) * 2013-05-28 2014-11-29 Fond Istituto Italiano Di Tecnologia COPOLYMER AND NANOPARTICLES OBTAINED FROM THEM FOR THE DRIVING OF A DRUG
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
CN104523592B (en) * 2015-01-26 2017-03-15 湖北工业大学 Methylprednisolone acetate injection self-micro emulsion formulation and preparation method thereof
ES2964696T3 (en) 2015-11-16 2024-04-09 Medincell S A A method of morselyzing and/or directing pharmaceutically active ingredients to synovial tissue
TWI777515B (en) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 Methods of treating eosinophilic esophagitis
EP4137323A1 (en) 2021-08-18 2023-02-22 Imertech Hydraulic binder with low carbon footprint and high early strength

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4716203A (en) * 1986-09-05 1987-12-29 American Cyanamid Company Diblock and triblock copolymers
DE3779838T2 (en) * 1986-09-05 1992-12-24 American Cyanamid Co COATING FOR SURGICAL THREADS.
ES2058081T3 (en) * 1986-09-05 1994-11-01 American Cyanamid Co POLYESTERS CONTAINING BLOCKS OF ALKYLENE OXIDE AS SYSTEMS FOR ADMINISTRATION OF MEDICINES.
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
DE4130933A1 (en) * 1991-09-13 1993-03-18 Schering Ag NEW (BETA) CARBOLINE DERIVATIVES, THEIR PRODUCTION AND USE IN MEDICINAL PRODUCTS
DE4219536A1 (en) * 1992-06-15 1993-12-16 Herbertz Heinz Centrifuge for dewatering articles in a washing machine - involves several washing articles loaded into centrifuge and centrifuged together at speed at which the centrifugal force acting on wash ring inner dia. is same as article wt.
JP3220331B2 (en) * 1993-07-20 2001-10-22 エチコン・インコーポレーテツド Absorbable liquid copolymers for parenteral administration
AU706434B2 (en) * 1994-10-18 1999-06-17 Ethicon Inc. Injectable liquid copolymers for soft tissue repair and augmentation
US6413539B1 (en) * 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5518774A (en) * 1995-06-26 1996-05-21 Olin Corporation In-can and dry coating antimicrobial
KR0180334B1 (en) * 1995-09-21 1999-03-20 김윤 Drug messenger using el-2l-2 micelle and method for sealing drug to it
ATE302599T1 (en) * 1996-05-24 2005-09-15 Angiotech Pharm Inc PREPARATIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF DISEASES OF THE BODY PASSAGES
AU6169998A (en) * 1997-02-14 1998-09-08 Chandrashekar Pathak Biocompatible polymers and methods for their use
US6211249B1 (en) * 1997-07-11 2001-04-03 Life Medical Sciences, Inc. Polyester polyether block copolymers
IL122933A (en) * 1998-01-14 2005-03-20 Efrat Biopolymers Ltd Polymeric carrier for delivery of a bioactive molecule
OA11674A (en) * 1998-11-10 2005-01-12 Janssen Pharmaceutica Nv HIV Replication inhibiting pyrimidines.
KR100288103B1 (en) * 1998-12-26 2001-05-02 윤덕용 Biodegradable aliphatic polyester grafted with polyether and its preparation method
CN100408099C (en) * 2000-11-09 2008-08-06 阿斯特拉曾尼卡有限公司 Oral pharmaceutical composition containing a block copolymer
US6617995B2 (en) * 2001-09-24 2003-09-09 Microline Co., Ltd. Radar detector
EP1327850B1 (en) * 2002-01-10 2006-05-17 Davey Bickford Electro-explosive initiator and method of manufacture

Similar Documents

Publication Publication Date Title
JP2005524730A5 (en)
CA2483282A1 (en) Polymeric microemulsions
US9913910B2 (en) Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
ES2469641T3 (en) Amphiphilic Polymeric Material
US20070264339A1 (en) Base-stabilized polyorthoester formulations
US20080015210A1 (en) Base-Stabilized Polyorthoester Formulations
WO2002085337B1 (en) Micellar drug delivery systems for hydrophobic drugs
US20060235084A1 (en) PEG-polyacetal diblock and triblock copolymers and pharmaceutical compositions
EP1499359A1 (en) Temperature responsive delivery systems
CA2601547A1 (en) Peg-poly(ortho ester) graft copolymers and pharmaceutical compositions
TW202206126A (en) Temperature sensitive composition for tissue adhesion prevention and application thereof
WO2014185309A1 (en) Substance for preventing adhesion and production method therefor
WO2008068641A2 (en) Degradable chewing gum
TH76143A (en)
TH77100A (en) Pharmaceutical mixtures